• Combined revenue scale: The acquisition of Organon will create an entity exceeding $12 billion in revenue, enabling Sun Pharma to expand its global commercial footprint and cross-pollinate product portfolios across markets.
• Organon segment strategy: Biosimilars is currently growing at 13%, while the flat established brands business (50% of revenue) will be targeted for growth via line extensions and new formulations.
• Women's health opportunity: Sun Pharma plans to pursue in-licensing opportunities from over 100 pipeline assets in the women's health sector, a $30–35 billion market growing at 5% to 7%.
• Integration and timeline: An integration office is being established immediately to assess talent and operational synergies, with the acquisition expected to close within approximately nine months.